Expression of osteopontin and osteonectin in breast cancer.

Expression of osteopontin and osteonectin in breast cancer.

Item
http://www.wikidata.org/entity/Q34656430
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesNuclear osteopontin-c is a prognostic breast cancer marker.Prognostic value of osteopontin expression in breast cancer: A meta-analysis.Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation.Matricellular proteins as regulators of cancer metastasis to bone.SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontinAssociation of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.Merlin: the wizard requires protein stability to function as a tumor suppressor.Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells.Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor.Inhibition of osteopontin reduces liver metastasis of human pancreatic cancer xenografts injected into the spleen in a mouse model.Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells.SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer.Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma.
P2860

Expression of osteopontin and osteonectin in breast cancer.

Item
http://www.wikidata.org/entity/Q34656430
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Expression of osteopontin and osteonectin in breast cancer.
@ast
Expression of osteopontin and osteonectin in breast cancer.
@en
Expression of osteopontin and osteonectin in breast cancer.
@nl
type
label
Expression of osteopontin and osteonectin in breast cancer.
@ast
Expression of osteopontin and osteonectin in breast cancer.
@en
Expression of osteopontin and osteonectin in breast cancer.
@nl
prefLabel
Expression of osteopontin and osteonectin in breast cancer.
@ast
Expression of osteopontin and osteonectin in breast cancer.
@en
Expression of osteopontin and osteonectin in breast cancer.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Expression of osteopontin and osteonectin in breast cancer.
@en
P2093
P304
P31
P356
10.3346/JKMS.1998.13.6.652
P433
P478
P577
P5875
P698
P932